Vyne Therapeutics Inc. (VYNE) Stock Price & Analysis
Vyne Therapeutics Inc. (VYNE) rose 1.84% to USD 0.67 as of June 10, 2026 at 07:05 UTC, according to Nexqual real-time market data.
VYNE last closed at USD 0.66; the session ranged USD 0.63–0.67 on volume of 76,597 shares. Market capitalization is $22.37M, with a 52-week range of USD 0.28–1.96 (NCM). Source: Nexqual, June 10, 2026 at 07:05 UTC.
Key Statistics (as of June 10, 2026 at 07:05 UTC)
| Price | USD 0.67 |
|---|---|
| Change | ▲ 1.84% (up) |
| Previous Close | USD 0.66 |
| Open | USD 0.67 |
| Day Range | USD 0.63 – 0.67 |
| 52-Week Range | USD 0.28 – 1.96 |
| Volume | 76,597 shares |
| Market Cap | $22.37M |
| Exchange | NCM |
Technical Analysis (VYNE)
Nexqual's technical model rates VYNE "NEUTRAL" based on 3 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 07:05 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 46.91 (neutral) |
| vs SMA50 | Above (USD 0.65) |
| MACD | 0 (positive) |
Analyst Ratings (VYNE)
Wall Street analysts rate VYNE "None", per Nexqual as of June 10, 2026 at 07:05 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 1 / 2 / 0 |
Earnings (VYNE)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.11 vs est -0.23 ▲ beat |
| 2025-09-30 | USD -0.17 vs est -0.13 ▼ miss |
| 2025-06-30 | USD -0.13 vs est -0.22 ▲ beat |
| 2025-03-31 | USD -0.2 vs est -0.29 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:05 UTC.
Financials & Fundamentals (VYNE)
| Total Revenue | $454,000 |
|---|---|
| Revenue Growth (YoY) | -57.40% |
| Gross Margin | +100.00% |
| Operating Margin | -4437.21% |
| Profit Margin | +0.00% |
| ROE | -63.16% |
| Current Ratio | 20.87 |
| Total Cash | $24.93M |
| Total Debt | $0 |
| Free Cash Flow | $-20.11M |
Source: Nexqual, June 10, 2026 at 07:05 UTC.
Financial Health Score (VYNE)
Nexqual rates Vyne Therapeutics Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:05 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $25M cash, no debt |
| Cash Flow | Weak — FCF negative: -$20M, burning cash |
| Efficiency | Critical — ROE -63%, ROA -37.0% |
Ownership (VYNE)
| Insider Ownership | +4.56% |
|---|---|
| Institutional Ownership | +41.71% |
| Shares Outstanding | 33.35M |
| Float | 32.55M |
| Short % of Float | +0.37% |
Source: Nexqual, June 10, 2026 at 07:05 UTC.
Leadership (VYNE)
Vyne Therapeutics Inc. is led by David T. Domzalski (age 58), CEO, President & Director, per Nexqual as of June 10, 2026 at 07:05 UTC.
| CEO, President & Director | David T. Domzalski (age 58) |
|---|---|
| Chief Scientific Officer | Iain A. Stuart (age 52) |
| CFO & Treasurer | Tyler Zeronda (age 38) |
Major Backers & Investors (VYNE)
Notable institutional backers of Vyne Therapeutics Inc. include Nantahala Capital Management, LLC, Lynx1 Capital Management Lp, Shay Capital LLC, according to Nexqual as of June 10, 2026 at 07:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Nantahala Capital Management, LLC | 6% |
| Lynx1 Capital Management Lp | 4.88% |
| Shay Capital LLC | 4.83% |
| Anson Funds Management LP | 3.73% |
| Adar1 Capital Management, LLC | 3.19% |
| T3 Companies, LLC | 2.83% |
| Braidwell LP | 2.75% |
| Citadel | 1.54% |
Source: Nexqual, June 10, 2026 at 07:05 UTC.
From Vyne Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- In general, new drug products require the submission of a New Drug Application ("NDA") and approval thereof by the FDA prior to being marketed in the United States.
- Special FDA Expedited Review and Approval Programs The FDA has various programs, including Fast Track designation, Breakthrough Therapy designation, Accelerated Approval, and Priority Review, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs.
- Development stage quantities of any products that we developed needed to be manufactured in facilities and by processes that complied with the requirements of the FDA and the regulatory agencies of other jurisdictions in which it may have sought approval.
- Intellectual Property Our intellectual property and proprietary technology are essential to the development of our product candidates.
Partnerships
- In addition, the relevant manufacturers of our product candidates for our prior preclinical and clinical trials advised us that they were compliant with both the FDA's Good Laboratory Practices ("GLP") and the FDA's current Good Manufacturing Practice ("cGMP") guidances. 8 Table of Contents Development and License Agreements Agreements with Tay Evaluation and Option Agreement In April 2021, we entered into an Evaluation and Option Agreement (the "Option Agreement") with Tay.
- License for Locally Administered Pan-BD BET Inhibitor Program (Repibresib) In August 2021, we exercised our option with respect to the repibresib program and entered into a license agreement (the "Repibresib License Agreement") granting us a worldwide, exclusive license that is sublicensable through multiple tiers to exploit certain of Tay's pan-BD BET inhibitor compounds in all fields.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INUV | Inuvo, Inc. | USD 1.41 | ▲ 0% |
| TTOO | T2 Biosystems, Inc. | USD 0 | ▲ 0% |
| MBAI | Check-Cap Ltd. | USD 1.4 | ▲ 1.45% |
| DARE | Dare Bioscience, Inc. | USD 1.92 | ▲ 2.13% |
| DCOY | Decoy Therapeutics Inc. | USD 5.51 | ▼ 16.64% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:05 UTC. This page is informational and not investment advice.